INDV
NASDAQIndivior Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$32.41-1.10 (-3.27%)
01:30 PM07:45 PM
News · 26 weeks49-56%
2026-04-192026-10-11
Mix2690d
- SEC Filings19(73%)
- Earnings3(12%)
- Insider2(8%)
- Dividends1(4%)
- Other1(4%)
Latest news
25 items- SECSEC Form 8-K filed by Indivior Pharmaceuticals Inc.8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- SECSEC Form 8-K filed by Indivior Pharmaceuticals Inc.8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form SCHEDULE 13G filed by Indivior Pharmaceuticals Inc.SCHEDULE 13G - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- SECIndivior Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- PRIndivior Pharmaceuticals, Inc. Declares Special Cash DividendRICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) ("Indivior") today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of record of the issued and outstanding Indivior common stock as of October 30, 2026 (the "Special Dividend Record Date") (such holders, the "Special Dividend Record Holders") and (ii) $8.13 per share of Indivior common stock underlying Indivior equity awards on the Special Dividend Record Date payable, upon vesting of such equity awards, to the holders of certain Indivior equity awards outstanding as of
- SECIndivior Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form EFFECT filed by Indivior Pharmaceuticals Inc.EFFECT - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form 424B3 filed by Indivior Pharmaceuticals Inc.424B3 - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECAmendment: SEC Form S-4/A filed by Indivior Pharmaceuticals Inc.S-4/A - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form S-4 filed by Indivior Pharmaceuticals Inc.S-4 - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- INSIDERChief Accounting Officer Anderson Woodrow D bought $53,535 worth of shares (1,500 units at $35.69), increasing direct ownership by 6% to 27,638 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERChief Accounting Officer Anderson Woodrow D bought $54,420 worth of shares (1,500 units at $36.28), increasing direct ownership by 6% to 26,138 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Filed by)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Filed by)
- SECSEC Form 10-Q filed by Indivior Pharmaceuticals Inc.10-Q - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- SECSEC Form 8-K filed by Indivior Pharmaceuticals Inc.8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- SECSEC Form 8-K filed by Indivior Pharmaceuticals Inc.8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- SECSEC Form 8-K filed by Indivior Pharmaceuticals Inc.8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- PRIndivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance• Q2’26 Total Net Revenue of $343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million and Record Non-GAAP Net Income of $142 Million in Q2'26 • Record Quarterly Adjusted EBITDA of $186 Million in Q2'26, Up 111% YoY • Repurchased Approximately 4.7 Million Shares in Q2'26 for $175 Million RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today reported its financial results for the second quarter ended June 30, 2026, and raised its full-year 2026 financial guidance. "Exceptional operational execution in Phase II – Accelerate – of
- PRSupernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant ScaleCombines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual revenuesEnhanced financial position and free cash flow generation enabling greater financial flexibility to pursue internal and external growth opportunitiesCombined company expected to benefit from immediate scale and $125 million of expected annual cost synergiesCombined entity to be named Supernus, Inc. and Jack Khattar to serve as President and Chief Executive Officer Companies to host joint conference call at 8:30 a.m. EDT today ROCKVILLE, Md. and RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and
INDV FAQ
5 questionsWhere does INDV stock trade?
Indivior Pharmaceuticals Inc. (INDV) is listed on NASDAQ.What sector and industry is INDV in?
Indivior Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INDV?
Indivior Pharmaceuticals Inc. has had 7 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $4600.00 price target on 2026-06-18. Recent price targets range from $1600.00 to $4600.00.What companies are similar to INDV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare INDV side-by-side with any of them on Quantisnow.How can I track INDV on Quantisnow?
Quantisnow aggregates Indivior Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INDV to receive live email and push alerts on every new disclosure.